Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific A2M CPAMD5, FWP007, S863-7 ENSG00000175899 Alpha-2-macroglobulin 12 9067664-9116229 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002265, CAB017621 Supported Expressed in all Expressed in all lung: 1921.7 ACE ACE1, CD143, DCP1 ENSG00000159640 Angiotensin I converting enzyme 17 63477061-63498380 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002426, CAB002921, HPA029298, HPA069790 Supported Approved Vesicles Expressed in all Tissue enhanced duodenum: 183.8;small intestine: 297.5 testis: 83.7 ADIPOQ ACDC, ACRP30, adiponectin, AdipoQ, apM1, GBP28 ENSG00000181092 Adiponectin, C1Q and collagen domain containing 3 186842690-186858463 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB046467, HPA051767 Uncertain Group enriched Tissue enriched 17 adipose tissue: 935.8 breast: 55.7 AGT SERPINA8 ENSG00000135744 Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 1 230702523-230714297 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001557, CAB025798 Supported Group enriched Tissue enhanced cerebral cortex: 227.1;liver: 649.2 gallbladder: 134.3 ALB ENSG00000163631 Albumin 4 73397114-73421412 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB006262, HPA031024, HPA031025 Supported Validated Endoplasmic reticulum
Golgi apparatus Stomach cancer:7.87e-4 (unfavourable) Tissue enriched Tissue enriched 221 liver: 105632.0 kidney: 478.5 ALDOC ENSG00000109107 Aldolase C, fructose-bisphosphate 17 28573115-28577264 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003282, CAB020828, HPA067442 Supported Supported Approved Nucleus
Nucleoli fibrillar center
Vesicles
Cytosol Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable) Tissue enriched Tissue enriched 7 cerebral cortex: 768.7 heart muscle: 110.6 APOA1 ENSG00000118137 Apolipoprotein A-I 11 116835751-116837950 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016778, HPA046715 Supported Approved Vesicles
Cytosol Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable) Tissue enriched Tissue enhanced liver: 8446.1;small intestine: 4222.2 duodenum: 1654.8 APOA2 ENSG00000158874 Apolipoprotein A-II 1 161222292-161223631 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025885 Supported Tissue enriched Tissue enriched 1053 liver: 18141.3 bone marrow: 17.2 APOA4 ENSG00000110244 Apolipoprotein A-IV 11 116820700-116823306 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001352, HPA002549, CAB068250, CAB068251, CAB068252 Supported Approved Vesicles Tissue enriched Group enriched 129 duodenum: 2273.3;small intestine: 3513.5 liver: 22.3 APOB ENSG00000084674 Apolipoprotein B 2 21001429-21044073 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016070, HPA049793 Supported Supported Vesicles
Cytosol Tissue enriched Group enriched 122 duodenum: 187.7;liver: 619.0;small intestine: 340.0 adipose tissue: 3.1 APOC1 ENSG00000130208 Apolipoprotein C-I 19 44914247-44919349 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA051518 Supported Liver cancer:1.15e-7 (favourable) Tissue enriched Tissue enriched 6 liver: 7217.4 adrenal gland: 1118.5 APOC2 ENSG00000234906 Apolipoprotein C-II 19 44946035-44949565 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA055877 Supported Tissue enriched Tissue enriched 40 liver: 257.4 small intestine: 6.4 APOC3 ENSG00000110245 Apolipoprotein C-III 11 116829706-116833072 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:6.87e-5 (unfavourable), Liver cancer:3.77e-4 (favourable) Tissue enriched Tissue enriched 7 liver: 8606.5 small intestine: 1203.1 APOD ENSG00000189058 Apolipoprotein D 3 195568702-195584205 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA040520 Supported Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable) Expressed in all Tissue enriched 7 breast: 4546.8 adipose tissue: 668.0 APOE AD2 ENSG00000130203 Apolipoprotein E 19 44905754-44909393 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB008363, HPA065539, HPA068768, CAB069921 Supported Approved Vesicles Expressed in all Expressed in all adrenal gland: 1810.4 APOH B2G1, BG ENSG00000091583 Apolipoprotein H (beta-2-glycoprotein I) 17 66212033-66256525 Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001654, HPA003732, CAB022214 Supported Supported Golgi apparatus Liver cancer:2.39e-7 (favourable), Renal cancer:1.10e-6 (unfavourable) Tissue enriched Tissue enriched 278 liver: 9066.2 kidney: 32.6 APOL1 APOL ENSG00000100342 Apolipoprotein L, 1 22 36253010-36267530 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018885, CAB056156 Supported Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all liver: 116.0 BDH1 BDH, SDR9C1 ENSG00000161267 3-hydroxybutyrate dehydrogenase, type 1 3 197509783-197573323 Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA030947, HPA058709 Approved Validated Mitochondria Renal cancer:7.12e-8 (favourable), Liver cancer:9.86e-7 (favourable), Cervical cancer:1.09e-4 (favourable) Expressed in all Tissue enriched 6 liver: 168.8 colon: 27.4 C3 ARMD9, C3a, C3b, CPAMD1 ENSG00000125730 Complement component 3 19 6677704-6730562 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003563, CAB004209, HPA020432 Supported Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable) Expressed in all Expressed in all liver: 2484.3 C4A C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG ENSG00000244731 Complement component 4A (Rodgers blood group) 6 31982024-32002681 Blood group antigen proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB009811, CAB032603, HPA046356, HPA048287, HPA050103 Approved Tissue enhanced Tissue enhanced liver: 46.2 thyroid gland: 28.2 C4B C4B1, C4B3, C4F, CH, CO4, CPAMD3 ENSG00000224389 Complement component 4B (Chido blood group) 6 32014762-32035418 Blood group antigen proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA046356, HPA048287, HPA050103 Approved Tissue enhanced Tissue enhanced adrenal gland: 59.8;liver: 65.6 kidney: 18.4 CCL2 GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF ENSG00000108691 Chemokine (C-C motif) ligand 2 17 34255218-34257203 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013676, HPA019163 Approved Approved Golgi apparatus
Vesicles Renal cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 412.4 CD40LG CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP ENSG00000102245 CD40 ligand X 136648193-136660390 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA045827 Supported Mixed Tissue enhanced lymph node: 19.0;tonsil: 14.7 appendix: 10.9 CETP BPIFF ENSG00000087237 Cholesteryl ester transfer protein, plasma 16 56961850-56983845 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Mixed Group enriched 6 adipose tissue: 36.8;liver: 21.6;lymph node: 47.1;placenta: 50.0;spleen: 79.2 thyroid gland: 8.4 CHGA ENSG00000100604 Chromogranin A 14 92923080-92935293 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000023, HPA017369, CAB040544, CAB055506, CAB058688 Supported Approved Vesicles Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable) Tissue enhanced Tissue enriched 8 parathyroid gland: 6987.1 adrenal gland: 822.0 CHIT1 CHI3, CHIT ENSG00000133063 Chitinase 1 (chitotriosidase) 1 203212827-203273641 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA010575 Approved Cervical cancer:2.02e-4 (favourable) Tissue enhanced Group enriched 9 bone marrow: 31.3;breast: 10.7;cervix, uterine: 13.4;lung: 53.2;lymph node: 21.5 prostate: 2.9 CKB CKBB ENSG00000166165 Creatine kinase, brain 14 103519659-103523111 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001254, CAB047313 Supported Supported Cytosol Renal cancer:4.02e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 476.4 CKM CKMM ENSG00000104879 Creatine kinase, muscle 19 45306414-45322977 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047859 Supported Group enriched Tissue enriched 15 skeletal muscle: 23804.3 heart muscle: 1618.7 CLU APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2 ENSG00000120885 Clusterin 8 27596917-27615031 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000476, HPA000572, CAB016253 Uncertain Thyroid cancer:7.66e-5 (favourable) Expressed in all Expressed in all epididymis: 10967.7 CP ENSG00000047457 Ceruloplasmin (ferroxidase) 3 149162410-149222055 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001834, CAB008591 Supported Renal cancer:1.14e-7 (unfavourable) Tissue enhanced Tissue enriched 10 liver: 916.4 cervix, uterine: 95.6 CPB2 CPU, PCPB, TAFI ENSG00000080618 Carboxypeptidase B2 (plasma) 13 46053186-46105076 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004146 Approved Liver cancer:2.06e-4 (favourable) Tissue enriched Tissue enriched 28 liver: 754.0 lung: 26.5 CRP PTX1 ENSG00000132693 C-reactive protein, pentraxin-related 1 159712289-159714589 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB005036, HPA027367, HPA027396 Supported Renal cancer:4.17e-10 (unfavourable) Tissue enriched Group enriched 68 gallbladder: 173.7;liver: 532.4 endometrium: 5.2 CSF1 M-CSF, MCSF, MGC31930 ENSG00000184371 Colony stimulating factor 1 (macrophage) 1 109910242-109930992 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA076624 Supported Plasma membrane Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 66.1 CTSB ENSG00000164733 Cathepsin B 8 11842524-11869448 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000457, HPA018156 Uncertain Supported Nucleoli
Vesicles Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 2885.5 CXCL8 3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1 ENSG00000169429 Chemokine (C-X-C motif) ligand 8 4 73740506-73743716 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA057179 Supported Approved Golgi apparatus Renal cancer:3.13e-6 (unfavourable), Cervical cancer:1.18e-5 (unfavourable), Liver cancer:1.19e-5 (unfavourable) Expressed in all Tissue enriched 7 bone marrow: 2079.8 appendix: 297.8 EDN1 ET1 ENSG00000078401 Endothelin 1 6 12290363-12297194 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA031976, CAB032500, CAB037291 Approved Approved Nucleus
Nucleoli
Golgi apparatus Expressed in all Mixed lung: 43.6 ENG CD105, END, HHT1, ORW, ORW1 ENSG00000106991 Endoglin 9 127815012-127854756 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB000096, HPA011862, HPA067440, CAB072873 Supported Liver cancer:5.62e-6 (favourable), Renal cancer:4.26e-4 (unfavourable), Head and neck cancer:6.61e-4 (favourable) Expressed in all Expressed in all spleen: 170.7 ENO2 ENSG00000111674 Enolase 2 (gamma, neuronal) 12 6913745-6923698 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000063, HPA068284, CAB073539 Supported Approved Nucleus
Plasma membrane
Cytosol Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 432.2 parathyroid gland: 64.5 ENO3 ENSG00000108515 Enolase 3 (beta, muscle) 17 4948092-4957131 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000793, HPA068284 Approved Validated Plasma membrane
Cytosol Colorectal cancer:7.33e-4 (unfavourable) Expressed in all Tissue enriched 19 skeletal muscle: 5975.8 heart muscle: 311.9 EPO EP ENSG00000130427 Erythropoietin 7 100720800-100723700 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins Evidence at protein level CAB010336 Supported Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable) Group enriched Tissue enhanced cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7 prostate: 1.1 F10 ENSG00000126218 Coagulation factor X 13 113122814-113149529 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable) Tissue enriched Tissue enhanced liver: 68.0 cervix, uterine: 51.6 F11 FXI ENSG00000088926 Coagulation factor XI 4 186265945-186288806 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039808 Approved Vesicles Liver cancer:3.29e-5 (favourable) Tissue enriched Tissue enhanced liver: 179.3 kidney: 44.4 F12 ENSG00000131187 Coagulation factor XII (Hageman factor) 5 177402140-177409576 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA003825 Approved Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable) Tissue enriched Tissue enriched 78 liver: 141.7 bone marrow: 1.8 F13A1 F13A ENSG00000124491 Coagulation factor XIII, A1 polypeptide 6 6144085-6321013 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA001804, CAB002155 Supported Renal cancer:6.61e-6 (unfavourable) Expressed in all Expressed in all placenta: 664.9 F13B FXIIIB ENSG00000143278 Coagulation factor XIII, B polypeptide 1 197039191-197067267 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003827, HPA052139 Supported Liver cancer:6.78e-5 (favourable) Tissue enriched Tissue enriched 108 liver: 122.1 duodenum: 1.1 F2 ENSG00000180210 Coagulation factor II (thrombin) 11 46719180-46739506 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016780, CAB018650, HPA051476, HPA054698 Supported Renal cancer:6.75e-12 (unfavourable) Tissue enriched Tissue enriched 1471 liver: 627.1 testis: 0.4 F3 CD142 ENSG00000117525 Coagulation factor III (thromboplastin, tissue factor) 1 94529225-94541800 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009438, HPA049292, HPA069132 Approved Validated Vesicles Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all placenta: 189.7 F5 ENSG00000198734 Coagulation factor V (proaccelerin, labile factor) 1 169514166-169586588 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002036 Uncertain Approved Golgi apparatus Stomach cancer:3.39e-4 (unfavourable) Tissue enriched Group enriched 11 gallbladder: 28.5;liver: 93.7;placenta: 67.7 fallopian tube: 5.8 F7 ENSG00000057593 Coagulation factor VII (serum prothrombin conversion accelerator) 13 113105788-113120681 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 44 liver: 65.2 testis: 1.4 F8 DXS1253E, F8C, FVIII, HEMA ENSG00000185010 Coagulation factor VIII, procoagulant component X 154835788-155026940 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018777 Supported Expressed in all Expressed in all lung: 23.4 F9 FIX ENSG00000101981 Coagulation factor IX X 139530758-139563458 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Liver cancer:6.69e-4 (favourable) Tissue enriched Tissue enriched 2286 liver: 364.7 kidney: 0.1 FABP3 FABP11, H-FABP, MDGI, O-FABP ENSG00000121769 Fatty acid binding protein 3, muscle and heart 1 31365625-31376850 Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017830, HPA055754 Supported Approved Golgi apparatus Renal cancer:1.54e-7 (favourable) Expressed in all Tissue enriched 6 heart muscle: 2838.6 skeletal muscle: 471.3 FAS APO-1, APT1, CD95, FAS1, TNFRSF6 ENSG00000026103 Fas cell surface death receptor 10 88990531-89015785 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027444 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed lung: 39.5 FGA ENSG00000171560 Fibrinogen alpha chain 4 154583126-154590766 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016776, HPA051370, HPA064755 Supported Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable) Tissue enriched Tissue enriched 246 liver: 9252.8 stomach: 37.6 FGB ENSG00000171564 Fibrinogen beta chain 4 154562956-154571086 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001900, HPA001901, CAB008624 Supported Renal cancer:5.72e-5 (unfavourable) Tissue enriched Tissue enriched 558 liver: 9991.3 kidney: 17.9 FGF2 FGFB ENSG00000138685 Fibroblast growth factor 2 (basic) 4 122826708-122898236 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB000125 Approved Supported Nucleoplasm
Nuclear bodies Pancreatic cancer:9.85e-4 (unfavourable) Mixed Mixed adipose tissue: 25.4 FGG ENSG00000171557 Fibrinogen gamma chain 4 154604134-154612967 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027529, CAB033120 Supported Renal cancer:1.00e-6 (unfavourable) Tissue enriched Tissue enriched 115 liver: 8684.7 lung: 75.3 FN1 CIG, FINC, GFND2, LETS, MSF ENSG00000115414 Fibronectin 1 2 215360440-215436172 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000126, HPA027066 Supported Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 4245.7 lung: 1168.8 FST FS ENSG00000134363 Follistatin 5 53480409-53487134 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA018155, CAB026025 Uncertain Renal cancer:4.44e-5 (unfavourable) Expressed in all Mixed liver: 32.8 FTH1 FHC, FTH, FTHL6, PIG15, PLIF ENSG00000167996 Ferritin, heavy polypeptide 1 11 61959718-61967660 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008623 Approved Approved Microtubules Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable) Expressed in all Expressed in all appendix: 5085.0 FTL MGC71996, NBIA3 ENSG00000087086 Ferritin, light polypeptide 19 48965301-48966878 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB020769, HPA041602 Supported Approved Cytosol Renal cancer:4.40e-5 (unfavourable) Expressed in all Expressed in all lung: 8051.2 GFAP FLJ45472 ENSG00000131095 Glial fibrillary acidic protein 17 44905008-44916937 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000039, HPA056030, HPA063513 Supported Supported Supported Intermediate filaments Tissue enriched Tissue enriched 431 cerebral cortex: 4111.0 bone marrow: 9.5 GGT1 CD224, D22S672, D22S732, GGT ENSG00000100031 Gamma-glutamyltransferase 1 22 24583750-24629005 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045635, HPA047534, HPA065444 Supported Approved Vesicles Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable) Expressed in all Tissue enhanced kidney: 160.6 small intestine: 97.9 GH1 GH, GH-N, GHN, hGH-N ENSG00000259384 Growth hormone 1 17 63917200-63918838 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA043715 Supported Not detected Tissue enhanced placenta: 1.2 duodenum: 0.7 GOT2 KAT4, KATIV, mitAAT ENSG00000125166 Glutamic-oxaloacetic transaminase 2, mitochondrial 16 58707131-58734357 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA018139 Supported Renal cancer:2.90e-9 (favourable), Liver cancer:5.75e-5 (favourable), Head and neck cancer:1.61e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 240.3 HABP2 FSAP, HABP, HGFAL, PHBP ENSG00000148702 Hyaluronan binding protein 2 10 113550837-113589602 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA019518 Approved Tissue enriched Group enriched 12 gallbladder: 56.0;liver: 225.6 stomach: 11.5 HEXA ENSG00000213614 Hexosaminidase A (alpha polypeptide) 15 72340919-72376476 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA054583 Supported Endometrial cancer:5.63e-8 (favourable) Expressed in all Expressed in all epididymis: 197.5 HGF DFNB39, F-TCF, HGFB, HPTA, SF ENSG00000019991 Hepatocyte growth factor (hepapoietin A; scatter factor) 7 81699006-81770438 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010333, HPA040360, HPA044088 Approved Approved Centrosome
Cytosol Renal cancer:5.59e-4 (unfavourable) Mixed Tissue enriched 16 placenta: 435.4 gallbladder: 27.6 HP ENSG00000257017 Haptoglobin 16 72054592-72061055 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB003787, HPA047750 Supported Approved Vesicles Renal cancer:6.94e-13 (unfavourable) Tissue enriched Tissue enriched 181 liver: 28321.0 bone marrow: 156.1 HPX ENSG00000110169 Hemopexin 11 6431049-6442617 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016725 Supported Liver cancer:2.26e-4 (favourable) Tissue enriched Tissue enriched 508 liver: 2610.6 breast: 5.1 ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Supported Uncertain Plasma membrane
Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 256.0 IGF1 IGF-I, IGF1A, IGFI ENSG00000017427 Insulin-like growth factor 1 (somatomedin C) 12 102395867-102480645 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA048946 Approved Endometrial cancer:1.04e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 126.3 smooth muscle: 97.4 IGFBP1 AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12 ENSG00000146678 Insulin-like growth factor binding protein 1 7 45888357-45893668 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB004445, HPA046972, HPA050640 Supported Approved Golgi apparatus Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable) Tissue enriched Group enriched 53 endometrium: 120.4;liver: 562.2;placenta: 264.8 fallopian tube: 5.9 IL10 CSIF, IL-10, IL10A, TGIF ENSG00000136634 Interleukin 10 1 206767602-206772494 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013120 Approved Mixed Tissue enhanced appendix: 8.9 adipose tissue: 7.4 IL18 IGIF, IL-18, IL-1g, IL1F4 ENSG00000150782 Interleukin 18 11 112143251-112164117 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003980, CAB007772 Supported Approved Nucleus
Golgi apparatus
Cytosol Colorectal cancer:2.78e-4 (favourable) Expressed in all Tissue enhanced esophagus: 133.6;skin: 171.9 lymph node: 73.1 IL1B IL-1B, IL1-BETA, IL1F2 ENSG00000125538 Interleukin 1, beta 2 112829751-112836903 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable) Mixed Tissue enhanced appendix: 69.5;bone marrow: 106.7 adipose tissue: 52.7 IL1RL1 DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1 ENSG00000115602 Interleukin 1 receptor-like 1 2 102311502-102352037 Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007406, HPA007917 Uncertain Approved Vesicles Tissue enhanced Tissue enriched 12 placenta: 286.6 gallbladder: 23.8 IL1RN ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430 ENSG00000136689 Interleukin 1 receptor antagonist 2 113107214-113134016 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001482, CAB009633 Supported Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 1248.5 tonsil: 301.6 IL2 IL-2, TCGF ENSG00000109471 Interleukin 2 4 122451470-122456725 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010310 Uncertain Not detected Not detected rectum,small intestine,tonsil: 0.3 IL6 BSF2, HGF, HSF, IFNB2, IL-6 ENSG00000136244 Interleukin 6 7 22725884-22732002 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB023406, CAB072821 Supported Approved Vesicles Renal cancer:1.10e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 135.4 urinary bladder: 76.8 IL6R CD126 ENSG00000160712 Interleukin 6 receptor 1 154405193-154469450 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.65e-4 (favourable) Expressed in all Expressed in all appendix: 34.4 IL6ST CD130, GP130 ENSG00000134352 Interleukin 6 signal transducer 5 55935095-55994993 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010558, CAB025784 Uncertain Supported Golgi apparatus
Plasma membrane Renal cancer:5.05e-4 (unfavourable) Expressed in all Expressed in all placenta: 327.1 INHBA ENSG00000122641 Inhibin, beta A 7 41685114-41703108 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA020031 Uncertain Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 28.7;gallbladder: 35.0 lung: 16.4 INS IDDM1, IDDM2 ENSG00000254647 Insulin 11 2159779-2161341 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000048, HPA004932, CAB012098, CAB053843 Supported Tissue enriched Tissue enriched 27 pancreas: 1850.8 skin: 68.1 ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Supported Uncertain Nucleoplasm
Cell Junctions
Cytosol Mixed Tissue enhanced bone marrow: 11.2;epididymis: 28.6 testis: 4.4 LCN2 24p3, NGAL ENSG00000148346 Lipocalin 2 9 128149071-128153455 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002695, CAB016549, CAB016550 Supported Breast cancer:9.61e-4 (favourable) Mixed Tissue enhanced bone marrow: 1855.7;gallbladder: 3437.6 cervix, uterine: 1153.6 LEP OB, OBS ENSG00000174697 Leptin 7 128241284-128257628 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010490 Approved Tissue enhanced Tissue enriched 11 adipose tissue: 321.7 breast: 29.4 LEPR CD295, OBR ENSG00000116678 Leptin receptor 1 65420652-65641559 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030899 Approved Vesicles Tissue enriched Mixed liver: 69.9 LPA LP ENSG00000198670 Lipoprotein, Lp(a) 6 160531483-160664259 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016072, HPA060604 Supported Tissue enriched Tissue enriched 26 liver: 41.5 seminal vesicle: 1.6 LPL LIPD ENSG00000175445 Lipoprotein lipase 8 19901717-19967258 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA048749 Approved Vesicles Urothelial cancer:6.07e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 974.6 parathyroid gland: 224.5 LRP1 A2MR, APOER, APR, CD91, LRP, LRP1A ENSG00000123384 Low density lipoprotein receptor-related protein 1 12 57128493-57213351 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004182, CAB018621, HPA022903 Supported Supported Nucleoli
Cytosol Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 123.2 MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau ENSG00000186868 Microtubule-associated protein tau 17 45894382-46028334 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000151, HPA048895, HPA069524, HPA069570 Supported Supported Nuclear speckles
Plasma membrane Group enriched Tissue enriched 8 cerebral cortex: 116.6 skeletal muscle: 13.7 MB PVALB ENSG00000198125 Myoglobin 22 35606764-35637951 Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000060, HPA003123 Supported Group enriched Group enriched 12 heart muscle: 6691.4;skeletal muscle: 12286.7 esophagus: 767.2 MBP ENSG00000197971 Myelin basic protein 18 76978827-77133683 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002300, HPA049222, HPA064368 Supported Supported Approved Plasma membrane Renal cancer:4.48e-12 (favourable) Group enriched Tissue enriched 30 cerebral cortex: 2938.8 parathyroid gland: 97.8 MME CALLA, CD10, NEP ENSG00000196549 Membrane metallo-endopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Supported Mixed Tissue enhanced duodenum: 440.1;kidney: 381.4;small intestine: 410.3 prostate: 151.9 MMP1 CLG ENSG00000196611 Matrix metallopeptidase 1 11 102789920-102798160 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004920 Supported Vesicles Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 39.7;gallbladder: 126.6 urinary bladder: 30.2 MMP2 CLG4, CLG4A, TBE-1 ENSG00000087245 Matrix metallopeptidase 2 16 55389700-55506691 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001939, CAB002788 Approved Uncertain Vesicles
Cytosol Expressed in all Tissue enhanced gallbladder: 1688.5 urinary bladder: 944.6 MMP3 STMY, STMY1 ENSG00000149968 Matrix metallopeptidase 3 11 102835801-102843803 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007875 Uncertain Approved Vesicles Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 26.9;endometrium: 58.7 urinary bladder: 9.2 MMP9 CLG4B ENSG00000100985 Matrix metallopeptidase 9 20 46008908-46016561 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201 Supported Approved Cytosol Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 253.0;lymph node: 119.4 appendix: 85.4 MPO ENSG00000005381 Myeloperoxidase 17 58269856-58280935 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000059, HPA021147, HPA061464 Supported Supported Nucleus
Vesicles Tissue enhanced Tissue enriched 81 bone marrow: 2504.1 salivary gland: 30.8 MYH11 SMHC, SMMHC ENSG00000133392 Myosin, heavy chain 11, smooth muscle 16 15703135-15857033 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002302, HPA014539, HPA015310 Supported Approved Plasma membrane
Cytosol Liver cancer:1.10e-5 (favourable) Tissue enhanced Tissue enhanced seminal vesicle: 1365.9;smooth muscle: 1008.5 prostate: 841.6 MYH6 ENSG00000197616 Myosin, heavy chain 6, cardiac muscle, alpha 14 23381990-23408277 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001239, HPA001349, CAB075723, CAB075724, CAB075725 Supported Tissue enriched Tissue enriched 111 heart muscle: 2135.5 skeletal muscle: 19.1 MYH7 CMD1S, CMH1, MPD1 ENSG00000092054 Myosin, heavy chain 7, cardiac muscle, beta 14 23412738-23435718 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001239, HPA001349, CAB015384 Supported Group enriched Group enriched 26 heart muscle: 1925.5;skeletal muscle: 5112.2 esophagus: 136.3 MYL2 CMH10 ENSG00000111245 Myosin, light chain 2, regulatory, cardiac, slow 12 110910819-110920722 Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA019763, HPA039262 Supported Uncertain Microtubules Head and neck cancer:2.60e-4 (unfavourable) Group enriched Group enriched 32 heart muscle: 13057.5;skeletal muscle: 9734.2 esophagus: 359.2 MYL3 CMH8, MLC1SB, MLC1V, VLC1 ENSG00000160808 Myosin, light chain 3, alkali; ventricular, skeletal, slow 3 46857872-46882169 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA016564, CAB018662, HPA046859, HPA063034 Supported Approved Vesicles Renal cancer:1.22e-8 (favourable) Tissue enhanced Group enriched 10 heart muscle: 1364.5;skeletal muscle: 1730.5 esophagus: 158.2 NGF NGFB ENSG00000134259 Nerve growth factor (beta polypeptide) 1 115285918-115338236 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Renal cancer:8.08e-7 (unfavourable), Head and neck cancer:1.80e-4 (unfavourable) Mixed Tissue enhanced ovary: 12.3 smooth muscle: 5.9 NPPA ANP, PND ENSG00000175206 Natriuretic peptide A 1 11845709-11848345 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA058269 Supported Supported Tissue enriched Tissue enriched 1175 heart muscle: 26555.9 epididymis: 22.5 NPPB ENSG00000120937 Natriuretic peptide B 1 11857464-11858931 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enriched 1602 heart muscle: 2863.6 testis: 1.7 ORM1 ENSG00000229314 Orosomucoid 1 9 114323056-114326475 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB006265, HPA046438, HPA047725, HPA057726 Approved Approved Golgi apparatus
Vesicles Renal cancer:2.35e-4 (unfavourable) Tissue enriched Tissue enriched 69 liver: 10546.0 bone marrow: 152.7 PAPPA ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1 ENSG00000182752 Pregnancy-associated plasma protein A, pappalysin 1 9 116153804-116402322 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001667, CAB016724 Supported Uncertain Plasma membrane
Cytosol Mixed Tissue enriched 7 placenta: 103.9 parathyroid gland: 14.6 PDGFA PDGF-A, PDGF1 ENSG00000197461 Platelet-derived growth factor alpha polypeptide 7 497258-520296 Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005579 Uncertain Approved Vesicles
Microtubule organizing center Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable) Expressed in all Expressed in all placenta: 39.1 PDGFB SIS, SSV ENSG00000100311 Platelet-derived growth factor beta polypeptide 22 39223359-39244751 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB011604, HPA011972, CAB018341 Supported Approved Vesicles Lung cancer:3.67e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 59.5 lung: 28.7 PF4 CXCL4, SCYB4 ENSG00000163737 Platelet factor 4 4 73981077-73982124 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB026008, HPA052485 Supported Tissue enhanced Group enriched 5 bone marrow: 53.9;spleen: 13.7 placenta: 6.4 PGAM1 PGAM-B, PGAMA ENSG00000171314 Phosphoglycerate mutase 1 (brain) 10 97426160-97433441 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042528, HPA049237, HPA060483 Approved Approved Nucleoplasm Breast cancer:2.04e-4 (unfavourable), Cervical cancer:3.86e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 422.5 PGF D12S1900, PGFL, PLGF, PlGF-2, SHGC-10760 ENSG00000119630 Placental growth factor 14 74941834-74955784 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA041624 Approved Nucleoplasm
Mitochondria
Cytosol Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 70.9;thyroid gland: 64.4 cervix, uterine: 29.9 PLA2G1B PLA2, PLA2A, PPLA2 ENSG00000170890 Phospholipase A2, group IB (pancreas) 12 120322111-120327789 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB022329, HPA047822, HPA060803 Supported Validated Cytosol Tissue enriched Tissue enriched 245 pancreas: 23848.8 ovary: 97.3 PLA2G7 LDL-PLA2, PAFAH ENSG00000146070 Phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) 6 46704201-46735693 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA035916 Uncertain Vesicles Expressed in all Mixed spleen: 38.1 PLAT ENSG00000104368 Plasminogen activator, tissue 8 42175233-42207724 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003412, CAB009335 Supported Approved Actin filaments Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 695.5 urinary bladder: 141.1 PLG ENSG00000122194 Plasminogen 6 160702238-160753315 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000668, CAB016678, HPA021602, HPA048823, HPA053770 Supported Uncertain Vesicles Renal cancer:4.22e-4 (favourable) Tissue enriched Tissue enriched 6 liver: 1748.3 kidney: 310.9 PON1 ESA, PON ENSG00000005421 Paraoxonase 1 7 95297676-95324707 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters Evidence at protein level HPA001610 Uncertain Liver cancer:7.24e-7 (favourable) Tissue enriched Tissue enriched 69 liver: 234.0 adrenal gland: 3.3 PON2 ENSG00000105854 Paraoxonase 2 7 95404863-95435329 Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025430, HPA029193 Supported Renal cancer:4.30e-8 (unfavourable), Cervical cancer:1.43e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 226.9 PON3 ENSG00000105852 Paraoxonase 3 7 95359944-95396368 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA014848, CAB025250 Supported Group enriched Tissue enriched 8 liver: 327.2 breast: 42.7 PROC ENSG00000115718 Protein C (inactivator of coagulation factors Va and VIIIa) 2 127418427-127429246 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005550, CAB016721, CAB016792 Supported Tissue enriched Tissue enriched 12 liver: 139.9 kidney: 12.0 PROCR CCD41, CD201, EPCR ENSG00000101000 Protein C receptor, endothelial 20 35172073-35216240 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039461 Supported Renal cancer:7.62e-6 (unfavourable) Expressed in all Expressed in all adipose tissue: 62.7 PROS1 PROS ENSG00000184500 Protein S (alpha) 3 93873033-93974066 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007724, HPA023974 Supported Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable) Expressed in all Tissue enhanced liver: 177.6 heart muscle: 75.3 PROZ PZ ENSG00000126231 Protein Z, vitamin K-dependent plasma glycoprotein 13 113158654-113172383 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA052006 Approved Liver cancer:3.46e-4 (favourable) Tissue enriched Group enriched 13 kidney: 14.5;liver: 27.4 testis: 1.6 PRTN3 ACPA, AGP7, C-ANCA, MBT, P29, PR-3 ENSG00000196415 Proteinase 3 19 840960-848175 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005938, CAB017558 Supported Tissue enhanced Tissue enriched 716 bone marrow: 617.7 spleen: 0.8 PYGB ENSG00000100994 Phosphorylase, glycogen; brain 20 25248069-25298014 Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031067 Approved Approved Cytosol Lung cancer:1.10e-4 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 148.6 REN ENSG00000143839 Renin 1 204154819-204166322 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA005131, CAB025903 Approved Renal cancer:6.45e-5 (unfavourable) Tissue enriched Tissue enhanced kidney: 50.8;placenta: 21.0 endometrium: 8.9 RETN ADSF, FIZZ3, RETN1 ENSG00000104918 Resistin 19 7669044-7670454 Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enriched 6 bone marrow: 159.8 lung: 26.1 S100B S100beta ENSG00000160307 S100 calcium binding protein B 21 46598962-46605208 Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins Evidence at protein level CAB000073, HPA015768, CAB078196 Supported Approved Nucleus
Vesicles Group enriched Group enriched 9 adipose tissue: 208.2;cerebral cortex: 628.0 seminal vesicle: 49.1 SAA2 ENSG00000134339 Serum amyloid A2 11 18239223-18248643 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Renal cancer:1.30e-8 (unfavourable) Tissue enriched Tissue enhanced adipose tissue: 708.4;cervix, uterine: 411.1;liver: 580.7 appendix: 215.3 SELE CD62E, ELAM, ELAM1, ESEL ENSG00000007908 Selectin E 1 169722641-169764705 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002143 Supported Mixed Tissue enhanced parathyroid gland: 44.4;prostate: 40.0 urinary bladder: 28.6 SELL CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR ENSG00000188404 Selectin L 1 169690667-169711698 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002144, HPA051972 Supported Uncertain Cytosol Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable) Expressed in all Tissue enhanced lymph node: 258.2;spleen: 222.6;tonsil: 185.9 appendix: 157.5 SELP CD62, CD62P, GMP140, GRMP, PADGEM, PSEL ENSG00000174175 Selectin P (granule membrane protein 140kDa, antigen CD62) 1 169588849-169630193 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002145, HPA002655, HPA005990 Supported Head and neck cancer:3.12e-4 (favourable) Mixed Mixed smooth muscle: 20.4 SELPLG CD162, PSGL-1 ENSG00000110876 Selectin P ligand 12 108622277-108633959 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002431 Supported Cervical cancer:1.46e-4 (favourable), Thyroid cancer:2.74e-4 (favourable), Melanoma:2.92e-4 (favourable), Renal cancer:5.86e-4 (unfavourable), Head and neck cancer:6.94e-4 (favourable) Expressed in all Mixed spleen: 86.7 SERPINA1 A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1 ENSG00000197249 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 14 94376747-94390693 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000927, HPA001292, CAB013211, CAB016648, CAB073396 Supported Validated Vesicles Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable) Tissue enriched Tissue enriched 19 liver: 15340.0 lung: 799.2 SERPINA3 AACT, ACT, alpha-1-antichymotrypsin ENSG00000196136 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 14 94612384-94624055 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000893, HPA002560, CAB016647 Supported Breast cancer:8.92e-4 (favourable) Mixed Group enriched 5 cervix, uterine: 133.1;liver: 607.5 gallbladder: 69.4 SERPINA5 PAI3, PCI, PLANH3, PROCI ENSG00000188488 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 14 94561442-94593120 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA056919 Approved Mitochondria Endometrial cancer:7.72e-4 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 516.7;liver: 406.5;testis: 816.1 gallbladder: 251.6 SERPINC1 AT3, ATIII, MGC22579 ENSG00000117601 Serpin peptidase inhibitor, clade C (antithrombin), member 1 1 173903804-173917378 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001816, CAB016790, HPA024007 Supported Liver cancer:3.40e-5 (favourable) Tissue enriched Tissue enriched 675 liver: 2511.4 kidney: 3.7 SERPIND1 D22S673, HC-II, HC2, HCF2, HLS2 ENSG00000099937 Serpin peptidase inhibitor, clade D (heparin cofactor), member 1 22 20773879-20787720 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB008639, HPA055767 Supported Approved Vesicles Endometrial cancer:4.09e-4 (favourable) Tissue enriched Tissue enriched 16 liver: 584.7 parathyroid gland: 35.5 SERPINE1 PAI, PAI1, PLANH1 ENSG00000106366 Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 7 101127089-101139266 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA050039 Approved Approved Cytosol Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 581.0;placenta: 595.2 adipose tissue: 213.2 SERPINF2 A2AP, AAP, ALPHA-2-PI, API, PLI ENSG00000167711 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 2 17 1742836-1755268 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001885, CAB024863 Approved Uncertain Nucleoplasm
Vesicles Liver cancer:2.26e-5 (favourable) Tissue enriched Tissue enhanced epididymis: 115.3;liver: 452.4 kidney: 63.1 SERPING1 C1-INH, C1IN, C1NH, HAE1, HAE2 ENSG00000149131 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 11 57597387-57614853 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026161, HPA048738 Supported Renal cancer:1.55e-4 (unfavourable), Ovarian cancer:8.03e-4 (favourable), Colorectal cancer:9.96e-4 (unfavourable) Expressed in all Expressed in all liver: 1365.4 SHBG ABP, MGC126834, MGC138391, TEBG ENSG00000129214 Sex hormone-binding globulin 17 7613946-7633383 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced liver: 32.9;testis: 13.8 small intestine: 7.6 TFPI EPI, LACI, TFI, TFPI1 ENSG00000003436 Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 2 187464230-187565760 Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA005575, CAB020842 Supported Approved Intermediate filaments
Cytosol Cervical cancer:2.02e-4 (unfavourable) Expressed in all Expressed in all placenta: 340.4 TGFB1 CED, DPD1, TGFB, TGFbeta ENSG00000105329 Transforming growth factor, beta 1 19 41301587-41353911 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000361, CAB073543 Approved Uncertain Cytosol Renal cancer:1.19e-8 (unfavourable), Head and neck cancer:3.38e-4 (unfavourable) Expressed in all Expressed in all spleen: 86.1 THBD CD141 ENSG00000178726 Thrombomodulin 20 23045633-23049741 Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB002425, HPA002982 Supported Approved Nucleoplasm
Cytosol Expressed in all Expressed in all lung: 73.4 THBS1 THBS, THBS-1, TSP, TSP-1, TSP1 ENSG00000137801 Thrombospondin 1 15 39581079-39599466 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB033678, HPA059756 Approved Approved Plasma membrane Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable) Expressed in all Expressed in all appendix: 585.7 TIMP1 CLGI, EPO, TIMP ENSG00000102265 TIMP metallopeptidase inhibitor 1 X 47582313-47586789 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB022360, HPA053417 Approved Approved Golgi apparatus Renal cancer:2.90e-11 (unfavourable), Colorectal cancer:2.09e-4 (unfavourable) Expressed in all Expressed in all appendix: 2083.7 TIMP2 CSC-21K ENSG00000035862 TIMP metallopeptidase inhibitor 2 17 78852977-78925387 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010203 Approved Expressed in all Expressed in all ovary: 1176.3 TNF DIF, TNF-alpha, TNFA, TNFSF2 ENSG00000232810 Tumor necrosis factor 6 31575567-31578336 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Mixed Tissue enhanced bone marrow: 3.7 lymph node: 1.3 TNFRSF11B OCIF, OPG, TR1 ENSG00000164761 Tumor necrosis factor receptor superfamily, member 11b 8 118923557-118952200 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level Urothelial cancer:3.88e-4 (unfavourable), Cervical cancer:6.22e-4 (unfavourable), Renal cancer:6.79e-4 (favourable) Expressed in all Tissue enriched 5 thyroid gland: 139.8 kidney: 25.5 TNFRSF1A CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60 ENSG00000067182 Tumor necrosis factor receptor superfamily, member 1A 12 6328757-6342114 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004102, CAB010309 Approved Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable) Expressed in all Expressed in all gallbladder: 140.8 TNFRSF1B CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80 ENSG00000028137 Tumor necrosis factor receptor superfamily, member 1B 1 12167003-12209228 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004796 Approved Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 103.0 spleen: 79.2 TNNI3 CMD2A, CMH7, TNNC1 ENSG00000129991 Troponin I type 3 (cardiac) 19 55151767-55157773 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009349, HPA046428 Supported Approved Vesicles
Cytosol Mixed Tissue enriched 158 heart muscle: 3237.3 breast: 20.4 TNNT2 CMD1D, CMH2, CMPD2 ENSG00000118194 Troponin T type 2 (cardiac) 1 201359008-201377762 Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB015371, HPA015774, HPA017888 Supported Uncertain Nucleus
Nucleoli
Focal adhesion sites Mixed Tissue enriched 199 heart muscle: 5036.0 skin: 25.2 TPM1 C15orf13, CMH3 ENSG00000140416 Tropomyosin 1 (alpha) 15 63042632-63071915 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000261, HPA009066, CAB017698, HPA047089, HPA053624 Supported Approved Actin filaments
Cytosol Urothelial cancer:7.30e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 6465.2 VEGFA VEGF, VEGF-A, VPF ENSG00000112715 Vascular endothelial growth factor A 6 43770184-43786487 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005429, CAB039240, HPA069116 Approved Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 455.6 VTN VN ENSG00000109072 Vitronectin 17 28367276-28373091 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016695, CAB016765, HPA060933 Supported Supported Endoplasmic reticulum
Vesicles Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable) Tissue enriched Tissue enriched 28 liver: 2540.4 gallbladder: 91.6 VWF F8VWF ENSG00000110799 Von Willebrand factor 12 5948874-6124770 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB001694, HPA001815, HPA002082, CAB072874, CAB072875 Supported Stomach cancer:2.31e-4 (unfavourable) Expressed in all Mixed adipose tissue: 154.4